NEW YORK (GenomeWeb) – The US Food and Drug Administration has cleared an assay on Quidel's Solana platform to detect and differentiate herpes simplex viruses types 1 and 2 and varicella-zoster virus.

The test does not require upfront DNA extraction, detecting HSV-1, HSV-2, and VZV DNA in cutaneous or mucocutaneous lesion samples from symptomatic patients, including specimens collected in transport media. The Solana platform employs the firm's helicase-dependent amplification technology, and processes up to 12 samples per run, with run time of about one-hour.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.